In recent years, studies have identified high expression of DLL3 (about 80%) in small-cell lung cancer (SCLC) and other high-grade neuroendocrine tumors (Saunders et al., 2015), with low expression in normal tissues, which provides potential for targeted therapies. This evidence concerns the gene DLL3 and small cell lung carcinoma.